At a Glance
| Methallylescaline | 25B-NBOMe | |
|---|---|---|
| Class | Psychedelic | Psychedelic |
| Routes | oral | insufflatedsublingual |
| Effects | 44 documented | 42 documented |
Methallylescaline, a Psychedelic, and 25B-NBOMe, a Psychedelic, are frequently compared by users looking to understand their relative effects, dosage profiles, and safety considerations. Both are classified as Psychedelics, meaning they share a common pharmacological foundation. They share 29 documented effects in common, with 15 effects unique to Methallylescaline and 13 unique to 25B-NBOMe. This side-by-side comparison covers dosage, duration, subjective effects, and safety to help you make informed decisions.
| Methallylescaline | 25B-NBOMe | |
|---|---|---|
| Class | Psychedelic | Psychedelic |
| Routes | oral | insufflatedsublingual |
| Effects | 44 documented | 42 documented |
| Interaction | Low Risk & Synergy | |
| Level | Dose |
|---|---|
| Threshold | 5 mg |
| Light | 15–25 mg |
| Common | 25–40 mg |
| Strong | 40–60 mg |
| Heavy | 60 mg |
| Level | Dose |
|---|---|
| Threshold | 25 µg |
| Light | 50–200 µg |
| Common | 200–350 µg |
| Strong | 350–500 µg |
| Level | Dose |
|---|---|
| Threshold | 50 µg |
| Light | 100–300 µg |
| Common | 300–500 µg |
| Strong | 500–700 µg |
Cross-tolerance exists; effects compound
No dangerous interactions recorded.
No dangerous interactions recorded.